IDH1 and glioblastoma: Oncogenic IDH mutations lead to decreased levels of α-ketoglutarate (α-KG) and accumulation of 2-hydroxyglutarate (2HG) [41], an oncometabolite linked to increased reactive oxygen species (ROS) production [42] and decreased mitochondrial respiration in GBM cells [43].